UT Southwestern Center for Translational Medicine (UL1/KL2/TL1)

UT 西南转化医学中心 (UL1/KL2/TL1)

• 批准号: 9065628
• 负责人: ROBERT Daniel TOTO
• 金额: $ 536.08万
• 依托单位: UT SOUTHWESTERN MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 2013
• 资助国家: 美国
• 起止时间: 2013-09-26 至 2018-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9065628
• 关键词: Applications Grants; Area; Award; Bioinformatics; Biometry; Clinical; Clinical Research; Communities; Community Health; Detection; Devices; Diagnosis; Disease; Elements; Environment; Funding; Genomics; Goals; Grant; Health; Health Personnel; Health Sciences; Home environment; Hospitals; Human; Instruction; Intervention; Knowledge; Leadership; Malignant Neoplasms; Medical; Movement; Outcomes Research; Patient-Focused Outcomes; Population Research; Population Sciences; Positioning Attribute; Prevention; Principal Investigator; Proteomics; Public Health; Recruitment Activity; Research; Research Infrastructure; Research Institute; Research Personnel; Resources; Scientist; Systems Biology; TNFSF15 gene; Texas; Training and Education; Translating; Translational Research; Translations; Validation; Vision; Work; biomedical informatics; clinical practice; commercialization; design; effective therapy; falls; improved; innovation; metabolomics; novel diagnostics; novel therapeutics; programs; stem cell biology; translational medicine

Program Director/Principal Investigator (Last, First, Middle): T o t O , R o b e r t D . PROJECT SUMMARY (See instmctions): The CTSA has had a major impact on the clinical and translational research (CTR) environment at UT Southwestern. Many new and highly successful programs in education and training, pilot grant awards, biomedical informatics (BMI), biostatistics, population research, community health sciences, and patient- centered outcomes research have been established. Concurrently, the CTSA stimulated UT Southwestern to invest heavily in CTR infrastructure by recruiting new clinical and translational researchers into leadership positions of major clinical departments, by creating a new research institute that focuses on stem cell biology and cancer and by greatly enhancing genomics, metabolomics, proteomics, bioinformatics, and systems biology. Two new, state-of-the art hospitals are under construction, to open in fall 2014, and they incorporate design elements that will support CTR. Our vision is to accelerate translation of new discoveries into clinical practice (T0-T4) by leveraging our scientific strengths. We will integrate and centralize our resources to work in an encouraging and collaborative research environment. Our three Specific Aims are to: 1) Enhance our Research Environment to Accelerate Translation of Discovery into Practice. We formed the Center for Translational Medicine (Center), directed by the CTSA PI, to serve as the new integrated home for our CTSA. The Center will coordinate and expand the clinical research enterprise while it educates clinical and translational researchers at every level. 2) Leverage Existinq and New Resources to Build on Four Innovative Programs in Translation including: a) Target Identification and Validation; b) Discovery in Humans; c) Intervention in Humans and d) Population Science and Community Engagement. 3) Share Knowledge and Discoverv. and Contribute to the Leadership of the National Consortium. We will share gains that are made in our programs in educational and translational research programs with the Texas Regional CTSA consortium and National CTSA Consortium. We will contribute to leadership in areas of translation including T0-T4 research, and discovery and commercialization of new drugs and devices. Our vision for accelerating CTR is well aligned with the new NCATS initiatives and takes full advantage of gains made in the previous funding. We will establish new and improved programs that will enable investigators to discover, translate and disseminate new knowledge that will improve the prevention, detection, diagnosis, and effective treatment of disease. RELEVANCE (See instructions): Improving the health of our nation requires a concerted effort by medical scientists, health care providers and public health policymakers. This grant application will provide the crucial infrastructure necessary for medical scientists to discover and apply new diagnostics and therapeutics for the detection, prevention, detection, diagnosis and effective treatment of disease. The goal is to accelerate the movement of these new discoveries into clinical practice to improve our nation's health in a safe and effective manner.

项目总监/首席调查员(最后、第一、中间)：TO TO，R o b e r t D. 项目总结(见说明)： CTSA对德克萨斯大学的临床和转化研究(CTR)环境产生了重大影响 西南部。许多新的和非常成功的教育和培训方案，试点资助金， 生物医学信息学(BMI)、生物统计学、人口研究、社区卫生科学和患者- 已经建立了以成果为中心的研究。同时，CTSA刺激了德克萨斯大学西南分校 通过招募新的临床和翻译研究人员进入领导层，在CTR基础设施上投入大量资金 主要临床科室的职位，通过创建一个专注于干细胞生物学的新研究所 通过极大地加强基因组学、代谢组学、蛋白质组学、生物信息学和系统 生物学。两家新的、最先进的医院正在建设中，将于2014年秋季开放，他们 纳入将支持CTR的设计元素。我们的愿景是加快新发现的转化 通过利用我们的科学优势将其转化为临床实践(T0-T4)。我们将整合和集中我们的 在鼓励和协作的研究环境中工作的资源。我们的三个具体目标是 为：1)改善我们的研究环境，加速将发现转化为实践。我们 成立了转化医学中心(Center)，由CTSA Pi指导，作为新的 为我们的CTSA提供集成的家。该中心将协调和扩大临床研究企业 同时，它还培养各个层次的临床和翻译研究人员。2)利用现有的和新的 以四个翻译创新方案为基础的资源，包括：a)目标识别和 确认；b)人类的发现；c)对人类的干预；d)人口科学和社区 订婚。3)共享知识和发现。并为国家的领导做出贡献 财团。我们将分享我们在教育和翻译研究项目中取得的成果 与德克萨斯地区CTSA财团和全国CTSA财团合作的项目。我们将为 在翻译领域的领先地位，包括T0-T4研究，以及新产品的发现和商业化 毒品和设备。 我们加快CTR的愿景与新的NCATS倡议非常一致，并充分 利用前一笔资金的收益。我们将建立新的和改进的计划，以 使调查人员能够发现、翻译和传播将改善预防的新知识， 疾病的检测、诊断和有效治疗。 相关性(请参阅说明)： 改善我们国家的健康需要医学科学家、卫生保健提供者和 公共卫生政策制定者。这项赠款申请将提供必要的关键基础设施 医学科学家将发现并应用新的诊断和治疗方法来检测、预防、 疾病的检测、诊断和有效治疗。目标是加快这些项目的发展 临床实践中的新发现，以安全有效的方式提高我国的健康水平。